HTAs Consider the Incorporation of RWE in Drug Assessments

A new edition of industry news highlights focuses on health technology assessments (HTAs) and their growing acceptance of real world evidence (RWE). These industry highlights are published twice a month in The Journal of Comparative Effectiveness Research.

“Read highlights from the latest instalment of Sreeram Ramagopalan’s (F. Hoffmann-La Roche, Basel, Switzerland) industry news round-up, which discusses some of the latest developments in real-world evidence (RWE) as it relates to health technology assessment (HTA) and acceptance of RWE by HTA agencies, and is published bi-monthly in our partner journal, the Journal of Comparative Effectiveness Research. The full update for February–March 2021, ‘R WE ready for reimbursement?’, is co-authored by Alex Simpson (F. Hoffmann-La Roche) and is now available to view online.” Read more here.

(Source: Sreeram Ramagopalan, The Evidence Base, 5/10/2021)